Literature DB >> 26562474

Mechanisms of epithelial-mesenchymal transition in proliferative vitreoretinopathy.

Shuai Yang1, Hui Li1, Min Li1, Fang Wang1.   

Abstract

Proliferative vitreoretinopathy (PVR) is a blinding disease characterized by the formation of epiretinal membranes through the wound repair process. Though the mechanisms of PVR development are still not fully understood, retinal pigment epithelial (RPE) cells are indicated to play the primary role in the pathogenesis of PVR. In the setting of PVR, RPE cells undergo a process named epithelial-mesenchymal transition (EMT), by which differentiated epithelial cells go through a phenotypic conversion that gives rise to the matrix-producing fibroblasts and myofibroblasts. Recent studies indicated that EMT in RPE cells is a main contributor of PVR and involves various growth factors/cytokines, transcriptional factors, and microRNAs. Targeting these factors/microRNAs suppresses the progression of EMT and thus may provide novel ideas for the treatment of PVR. This review highlights the current understandings of EMT in the pathogenesis of PVR and the underlying mechanisms of EMT in RPE cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26562474

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  32 in total

1.  The effects of pleiotrophin in proliferative vitreoretinopathy.

Authors:  Xue Ding; Yujing Bai; Xuemei Zhu; Tianqi Li; Enzhong Jin; Lvzhen Huang; Wenzhen Yu; Mingwei Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-12       Impact factor: 3.117

Review 2.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

Review 3.  [Proliferative vitreoretinopathy (PVR) surgery: Scar Wars : Five steps to successful treatment of PVR detachment].

Authors:  S G Priglinger; J Siedlecki; L-O Hattenbach; S Grisanti
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

4.  Proteome-wide Identification of Glycosylation-dependent Interactors of Galectin-1 and Galectin-3 on Mesenchymal Retinal Pigment Epithelial (RPE) Cells.

Authors:  Jara Obermann; Claudia S Priglinger; Juliane Merl-Pham; Arie Geerlof; Sigfried Priglinger; Magdalena Götz; Stefanie M Hauck
Journal:  Mol Cell Proteomics       Date:  2017-06-02       Impact factor: 5.911

Review 5.  Immune Cells in Subretinal Wound Healing and Fibrosis.

Authors:  Manon Szczepan; María Llorián-Salvador; Mei Chen; Heping Xu
Journal:  Front Cell Neurosci       Date:  2022-06-10       Impact factor: 6.147

6.  Changes in transepithelial electrical resistance and intracellular ion concentration in TGF-β-induced epithelial-mesenchymal transition of retinal pigment epithelial cells.

Authors:  Minli Wang; Jiayi Wei; Hui Li; Fang Wang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

Review 7.  Extracellular vesicle therapy for retinal diseases.

Authors:  Ben Mead; Stanislav Tomarev
Journal:  Prog Retin Eye Res       Date:  2020-03-10       Impact factor: 19.704

8.  Long Non-Coding RNA MALAT1 Mediates Transforming Growth Factor Beta1-Induced Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells.

Authors:  Shuai Yang; Haipei Yao; Min Li; Hui Li; Fang Wang
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

9.  MicroRNA-182 Suppresses HGF/SF-Induced Increases in Retinal Pigment Epithelial Cell Proliferation and Migration through Targeting c-Met.

Authors:  Lihua Wang; Feng Dong; Peter S Reinach; Dandan He; Xiaoting Zhao; Xiaoyan Chen; Dan-Ning Hu; Dongsheng Yan
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

10.  Vitreous hemorrhage and Rhegmatogenous retinal detachment that developed after botulinum toxin injection to the extraocular muscle: case report.

Authors:  Dong Hyun Lee; Jinu Han; Sueng-Han Han; Sung Chul Lee; Min Kim
Journal:  BMC Ophthalmol       Date:  2017-12-13       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.